《即日市评》离岸人币弱港股吐 沽空率攀升 石药逆市扬
市场关注全国人大会议明天将表决「港版国安法」及本港政局，恒指於连升两日(累升454点或2%)後，今日回吐。投资者同时关注中美关系恶化，美国总统特朗普表示，本周内将采取强烈行动回应中国政府推行「港版国安法」，但未透露细节，当被问到是否会实施制裁时，他指这是一些周末前会听到的事，他个人认为将会很有力；执笔之时美股道指期货升194点或0.8%，美汇指数处99.1470。离岸人民币续走弱并跌穿7.17创近九个月低，人行今日开展1,200亿元人民币逆回购操，上证综指跌0.3%收2,836，内地创业板指数跌近2%，沪深两市成交额共5,732亿人民币。
恒指高开130点後掉头向下，曾倒跌250点低见23,134点，最终全日跌83点或0.4%，收23,301点；国指跌27点或0.3%，收9,567点。大市全日成交总额1,108.82亿元，沪、深港通南下交易录得净流入金额分别为3.6亿及12.38亿元。科网股偏软，腾讯(00700.HK)、美团点评(03690.HK)及阿里巴巴(09988.HK)股价各走低1.3%、2.6%及1.8%。
【离岸人币弱 港股呈回吐】
金融股偏好，汇控(00005.HK)股价升1.2%，港交所(00388.HK)微升0.1%收272.8元。港交所公布，旗下全资附属期交所已与MSCI Limited(MSCI)签订协议。根据协议，MSCI同意授权期交所使用MSCI亚洲及新兴市场股票指数，据有关指数在期交所初步推出37只期货及期权合约。
摩根大通发表告表示，新加坡交易所早上宣布将於2021年2月以後终止与MSCI亚洲及新兴市场期货及期权合约合作，MSCI转与港交所合作；该行认为，上述消息对港交所影响正面，料未来2至3年可提升其每股盈利预测5至15%，予其「增持」评级及目标价275元，并认为港交所与MSCI进行合作将是公司加快多元化发展的重要一步。
【沽空率攀升 石药逆市弹】
港股今日市宽转弱，主板股票的升跌比率为15比28(上日32比13)，下跌股份1,059只(跌幅2.8%)，恒指成份股有17只股份上升，32只股份录下跌，升跌比率为34比64(上日为98比2)。大市今日录沽空187.69亿元，占可沽空股份成交913.32亿元的20.55%(上日18.98%)。
石药集团(01093.HK)午後股价抽上6.7%收16.94元。石药公布今年首季营业额61.25亿元人民币按年升11.5%。纯利11.59亿人民币按年升21.8%；每股盈利18.59分。不派息。期内，毛利为45.29亿人民币按年增长17.9%；经营溢利11.63亿人民币，按年微升0.6%。按业务划分，首季成药收入按年升18.3%至50.22亿人民币；维生素C收入跌18.6%至4.26亿人民币；抗生素收入跌40.1%至2.08亿人民币。而石药拟进行人民币股份或中国存托凭证发行及在科创板上市。
摩根士丹利表报告表示，石药拟进行人民币股份或中国存托凭证发行及在科创板上市，料发行股份在总体股本10%内，集资所得用作投资研发及未来发展机会用途上。大摩并指公司今年销售按年升12%符预期，经调整溢利按年跌8%至8.73亿元，低於预期，主要是销售及分销成本(SG&A)较高所拖累，该行予石药「增持」评级及目标价22.5元。(wl/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
